A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis - PubMed (original) (raw)
Clinical Trial
A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis
Eleanor Barrager et al. J Altern Complement Med. 2002 Apr.
Abstract
Background: Seasonal allergic rhinitis (SAR) affects more than 23 million Americans annually, and current epidemiologic studies indicate that its prevalence within the United States is increasing. Numerous clinical observations and case studies have led researchers to hypothesize that methylsulfonylmethane (MSM) may help ameliorate the symptoms associated with SAR.
Objective: The primary goal of this study was to evaluate the efficacy of MSM in the reduction of SAR-associated symptoms. This study also examined possible adverse reactions associated with methylsulfonylmethane supplementation. Finally, this study attempted to elucidate the method of action by which MSM elicits its effect on allergy symptoms.
Design: Fifty-five (55) subjects were recruited for the study. All met the criteria for participation in the study. 50 subjects completed the study. Those subjects completing the study consumed 2,600 mg of MSM orally per day for 30 days. Clinical respiratory symptoms and energy levels were evaluated by a Seasonal Allergy Symptom Questionnaire (SASQ) at baseline and on days 7, 14, 21, and 30. Immune and inflammatory reactions were measured by plasma immunoglobulin E (IgE) and C-reactive protein at baseline and on day 30. An additional inflammatory biomarker, plasma histamine, was measured in a subset of subjects (n = 5).
Results: Day 7 upper and total respiratory symptoms were reduced significantly from baseline (p < 0.01 and p < 0.005, respectively). Lower respiratory symptoms were significantly improved from baseline by week 3 (p < 0.001). All respiratory improvements were maintained through the 30-day visit. Energy levels increased significantly by day 14 (p < 0.0001); this increase continued through day 30. No significant changes were observed in plasma IgE or histamine levels. The results of this study are promising. It would be worthwhile to conduct a larger, randomized, double-blind, placebo-controlled study to establish further if MSM would be a useful agent in the treatment of symptoms associated with SAR.
Conclusion: The results of this study suggest that MSM supplementation of 2,600 mg/day for 30 days may be efficacious in the reduction of symptoms associated with SAR. Furthermore, few side effects are associated with the use of this compound. Recent acute and subacute chronic toxicologic data on the same source of MSM as used in this study, further validate the safety of this product.
Comment in
- Methylsulfonylmethane as a treatment for seasonal allergic rhinitis: more data needed on pollen counts and questionnaire.
Gaby AR. Gaby AR. J Altern Complement Med. 2002 Jun;8(3):229. doi: 10.1089/10755530260127925. J Altern Complement Med. 2002. PMID: 12165181 No abstract available.
Similar articles
- Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G; Omalizumab Seasonal Allergic Rhinitis Trail Group. Casale TB, et al. JAMA. 2001 Dec 19;286(23):2956-67. doi: 10.1001/jama.286.23.2956. JAMA. 2001. PMID: 11743836 Clinical Trial. - Speed of onset of action of Tilarin.
Donnelly A, Bernstein DI, Goldstein S, Grossman J, Schwartz HJ, Casale TB. Donnelly A, et al. Allergy. 1996;51(28 Suppl):14-9. doi: 10.1111/j.1398-9995.1996.tb04774.x. Allergy. 1996. PMID: 8651472 Free PMC article. Clinical Trial. - Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis.
Brien S, Prescott P, Bashir N, Lewith H, Lewith G. Brien S, et al. Osteoarthritis Cartilage. 2008 Nov;16(11):1277-88. doi: 10.1016/j.joca.2008.03.002. Epub 2008 Apr 15. Osteoarthritis Cartilage. 2008. PMID: 18417375 Review. - Methylsulfonylmethane (MSM). Monograph.
[No authors listed] [No authors listed] Altern Med Rev. 2003 Nov;8(4):438-41. Altern Med Rev. 2003. PMID: 14653770 Review. No abstract available.
Cited by
- Effects of Methylsulfonylmethane on UVB-induced Skin Damage: An Experimental Study in a Mouse Model.
Chu SG, Chang YJ, Ryu JY, Lee JS, Choi KY, Chung HY, Cho BC, Yang JD. Chu SG, et al. In Vivo. 2022 Nov-Dec;36(6):2714-2721. doi: 10.21873/invivo.13007. In Vivo. 2022. PMID: 36309396 Free PMC article. - MSM ameliorates HIV-1 Tat induced neuronal oxidative stress via rebalance of the glutathione cycle.
Kim SH, Smith AJ, Tan J, Shytle RD, Giunta B. Kim SH, et al. Am J Transl Res. 2015 Feb 15;7(2):328-38. eCollection 2015. Am J Transl Res. 2015. PMID: 25893035 Free PMC article. - Omega-3 fatty acid supplementation provides an additional benefit to a low-dust diet in the management of horses with chronic lower airway inflammatory disease.
Nogradi N, Couetil LL, Messick J, Stochelski MA, Burgess JR. Nogradi N, et al. J Vet Intern Med. 2015 Jan;29(1):299-306. doi: 10.1111/jvim.12488. Epub 2014 Oct 10. J Vet Intern Med. 2015. PMID: 25307169 Free PMC article. Clinical Trial. - Evaluating the Impacts of Methylsulfonylmethane on Allergic Rhinitis After a Standard Allergen Challenge: Randomized Double-Blind Exploratory Study.
Hewlings S, Kalman DS. Hewlings S, et al. JMIR Res Protoc. 2018 Nov 29;7(11):e11139. doi: 10.2196/11139. JMIR Res Protoc. 2018. PMID: 30497995 Free PMC article. - Cytotoxicity of methylsulfonylmethane on gastrointestinal (AGS, HepG2, and KEYSE-30) cancer cell lines.
Jafari N, Bohlooli S, Mohammadi S, Mazani M. Jafari N, et al. J Gastrointest Cancer. 2012 Sep;43(3):420-5. doi: 10.1007/s12029-011-9291-z. J Gastrointest Cancer. 2012. PMID: 21626237
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous